Drug Screening Assays, Antitumor

"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.

Descriptor ID	D004354
MeSH Number(s)	E01.370.225.500.388 E05.200.500.388 E05.242.417 E05.337.550.200
Concept/Terms	Drug Screening Assays, Antitumor Drug Screening Assays, Antitumor Antitumor Drug Screening Assays Cancer Drug Tests Cancer Drug Test Drug Test, Cancer Drug Tests, Cancer Test, Cancer Drug Tests, Cancer Drug Drug Screening Tests, Tumor-Specific Drug Screening Tests, Tumor Specific Antitumor Drug Screens Antitumor Drug Screen Drug Screen, Antitumor Drug Screens, Antitumor Screen, Antitumor Drug Screens, Antitumor Drug Anti-Cancer Drug Screens Anti Cancer Drug Screens Anti-Cancer Drug Screen Drug Screen, Anti-Cancer Drug Screens, Anti-Cancer Screen, Anti-Cancer Drug Screens, Anti-Cancer Drug Anticancer Drug Sensitivity Tests Tumor-Specific Drug Screening Tests Tumor Specific Drug Screening Tests Dye Exclusion Assays, Antitumor Dye Exclusion Assays, Antitumor

Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Diagnostic Techniques and Procedures [E01.370]
Clinical Laboratory Techniques [E01.370.225]
Cytological Techniques [E01.370.225.500]
Drug Screening Assays, Antitumor [E01.370.225.500.388]
Investigative Techniques [E05]
Clinical Laboratory Techniques [E05.200]
Cytological Techniques [E05.200.500]
Drug Screening Assays, Antitumor [E05.200.500.388]
Cytological Techniques [E05.242]
Drug Screening Assays, Antitumor [E05.242.417]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]

Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".

Drug Screening Assays, Antitumor
Tumor Stem Cell Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.

Bar chart showing 74 publications over 25 distinct years, with a maximum of 8 publications in 2014 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	0	2	2
1993	1	0	1
1995	1	0	1
1997	0	1	1
1998	0	1	1
1999	1	2	3
2001	0	3	3
2003	0	1	1
2004	0	3	3
2005	0	6	6
2006	2	0	2
2007	0	2	2
2008	0	4	4
2009	0	3	3
2010	0	2	2
2011	0	6	6
2012	0	2	2
2014	0	8	8
2015	0	3	3
2016	0	4	4
2017	0	1	1
2018	0	3	3
2019	0	3	3
2020	1	7	8
2021	0	1	1

Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.

Choudhary S, Doshi A, Luckett-Chastain L, Ihnat M, Hamel E, Mooberry SL, Gangjee A. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem. 2021 04 01; 35:116061.

View in: PubMed
Zeng B, Glicksberg BS, Newbury P, Chekalin E, Xing J, Liu K, Wen A, Chow C, Chen B. OCTAD: an open workspace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features. Nat Protoc. 2021 02; 16(2):728-753.

View in: PubMed
Xiang W, Quadery TM, Hamel E, Luckett-Chastain LR, Ihnat MA, Mooberry SL, Gangjee A. The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity. Bioorg Med Chem. 2021 01 01; 29:115887.

View in: PubMed
Sundriyal S, Eeda V, Lagisetty P, Awasthi V. Tubulin inhibitory activity of a novel colchicine-binding compounds based on a dinaphthospiropyranran scaffold. Bioorg Med Chem. 2021 01 01; 29:115874.

View in: PubMed
Elayapillai S, Ramraj S, Benbrook DM, Bieniasz M, Wang L, Pathuri G, Isingizwe ZR, Kennedy AL, Zhao YD, Lightfoot S, Hunsucker LA, Gunderson CC. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.

View in: PubMed
He G, Pan X, Liu X, Zhu Y, Ma Y, Du C, Liu X, Mao C. HIF-1a-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo. ACS Appl Mater Interfaces. 2020 Oct 28; 12(43):48296-48309.

View in: PubMed
Lagisetty P, Eeda V, Yadav VR, Nimmo SL, Subramaniam D, Powell DR, Awasthi V. Tumor suppressive activities of solvatochromic 3,3'-azadimethylene dinaphthospiropyran in colon cancer model. Chem Biol Drug Des. 2021 02; 97(2):325-340.

View in: PubMed
Pederson PJ, Cai S, Carver C, Powell DR, Risinger AL, Grkovic T, O'Keefe BR, Mooberry SL, Cichewicz RH. Triple-Negative Breast Cancer Cells Exhibit Differential Sensitivity to Cardenolides from Calotropis gigantea. J Nat Prod. 2020 07 24; 83(7):2269-2280.

View in: PubMed
Kil YS, Risinger AL, Petersen CL, Mooberry SL, Cichewicz RH. Leucinostatins from Ophiocordyceps spp. and Purpureocillium spp. Demonstrate Selective Antiproliferative Effects in Cells Representing the Luminal Androgen Receptor Subtype of Triple Negative Breast Cancer. J Nat Prod. 2020 06 26; 83(6):2010-2024.

View in: PubMed
Chappel L, Wong LC, Leong CO, Mai CW, Meikle IT, Stanforth SP, Truong TV. The synthesis of trifluoromethylated N-nitroaryl-2-amino-1,3-dichloropropane derivatives and their evaluation as potential anti-cancer agents. Bioorg Med Chem Lett. 2020 02 15; 30(4):126910.

View in: PubMed

People

Explore

Similar Concepts

Top Journals